{"id":21382,"date":"2024-04-19T11:51:09","date_gmt":"2024-04-19T15:51:09","guid":{"rendered":"https:\/\/oldals.thedev.ca\/?page_id=21382"},"modified":"2024-04-19T11:51:09","modified_gmt":"2024-04-19T15:51:09","slug":"lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation","status":"publish","type":"page","link":"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/","title":{"rendered":"L&#8217;essai TUDCA n&#8217;a pas r\u00e9pondu \u00e0 ses crit\u00e8res d&#8217;\u00e9valuation"},"content":{"rendered":"<p><strong>Le 4 avril 2024 <\/strong>\u2013 L&#8217;<a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fwww.tudca.eu%2Ftop-line-results-announcement%2F&amp;data=05%7C02%7Cjasselin%40oldals.thedev.ca%7C76bf37e64aea420e2d2408dc54ac4750%7Cc7bb930631594c778981516ad1fa13e2%7C0%7C0%7C638478346116858090%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&amp;sdata=J4%2B2vfe2GxFJjdnHeqVsLs0ReUYZ7X3AOp7s%2Fi%2BsaaU%3D&amp;reserved=0\" target=\"_blank\" rel=\"noopener\">annonce<\/a> des r\u00e9sultats globaux de l&#8217;essai clinique de phase 3 sur TUDCA en Europe a r\u00e9v\u00e9l\u00e9 que l&#8217;essai n&#8217;a pas r\u00e9pondu aux crit\u00e8res d&#8217;\u00e9valuation, \u00e9tant donn\u00e9 que TUDCA n&#8217;a pas d\u00e9montr\u00e9 sa capacit\u00e9 \u00e0 alt\u00e9rer de mani\u00e8re significative la progression de la SLA, selon les mesures de l&#8217;ALS Functional Rating Scale \u2013 Revised (ALSFRS-R). De plus, les mesures suppl\u00e9mentaires (crit\u00e8res d&#8217;\u00e9valuation secondaires) n&#8217;ont pas pu mettre en \u00e9vidence un avantage de TUDCA. Celles-ci comprenaient une \u00e9valuation par rapport \u00e0 l&#8217;effet sur la survie et les biomarqueurs cl\u00e9s, y compris des neurofilaments \u00e0 cha\u00eene l\u00e9g\u00e8re (NfL), ainsi que plusieurs d&#8217;autres analyses.<\/p>\n<p>L&#8217;essai clinique TUDCA-ALS de phase 3 \u00e9tait une \u00e9tude randomis\u00e9e, \u00e0 double insu, contr\u00f4l\u00e9e contre placebo, testant un r\u00e9gime de quatre g\u00e9lules orales (250 mg), deux fois par jour, aupr\u00e8s de 336 participants sur une p\u00e9riode de 18 mois. Il s&#8217;agissait d&#8217;un essai universitaire (\u00e9galement qualifi\u00e9 comme \u00ab \u00e0 l&#8217;initiative de chercheurs \u00bb) men\u00e9 par le consortium de cliniciens britanniques et europ\u00e9ens sp\u00e9cialis\u00e9s dans la SLA sur TUDCA-ALS, c&#8217;est-\u00e0-dire qu&#8217;il n&#8217;a pas b\u00e9n\u00e9fici\u00e9 de l&#8217;appui d&#8217;une soci\u00e9t\u00e9 pharmaceutique. Le consortium a d\u00e9clar\u00e9 rechercher d&#8217;autres analyses statistiques pour mieux comprendre s&#8217;il y avait un b\u00e9n\u00e9fice potentiel de TUDCA dans un sous-groupe d&#8217;invidus. Certaines de ces donn\u00e9es devraient \u00eatre pr\u00e9sent\u00e9es en juin lors de la r\u00e9union de l\u2019European Network for the Cure of ALS (ENCALS) en Su\u00e8de. La Soci\u00e9t\u00e9 canadienne de la SLA tiendra la communaut\u00e9 au courant au fur et \u00e0 mesure que de nouvelles informations seront disponibles.<\/p>\n<p>TUDCA ou acide tauroursod\u00e9soxycholique (\u00e9galement connu comme TURSO) est l&#8217;un des deux m\u00e9dicaments compos\u00e9s dans Albrioza (\u00e9galement d\u00e9nomm\u00e9 Relyvrio et AMX0035), lequel a r\u00e9cemment \u00e9t\u00e9 d\u00e9clar\u00e9 inefficace sur les r\u00e9sultats primaires et secondaires d&#8217;un essai clinique de phase 3.<\/p>\n<p>Si vous souhaitez discuter de l&#8217;utilisation de TUDCA, consultez votre clinicien.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le 4 avril 2024 \u2013 L&#8217;annonce des r\u00e9sultats globaux de l&#8217;essai clinique de phase 3 sur TUDCA en Europe a r\u00e9v\u00e9l\u00e9 que l&#8217;essai n&#8217;a pas r\u00e9pondu aux crit\u00e8res d&#8217;\u00e9valuation, \u00e9tant donn\u00e9 que TUDCA n&#8217;a pas d\u00e9montr\u00e9 sa capacit\u00e9 \u00e0 alt\u00e9rer de mani\u00e8re significative la progression de la SLA, selon les mesures de l&#8217;ALS Functional Rating [&hellip;]<\/p>\n","protected":false},"author":29,"featured_media":0,"parent":1569,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_stc_notifier_status":"","_stc_notifier_sent_time":"","_stc_notifier_request":false,"_stc_notifier_prevent":false,"_stc_subscriber_keywords":"","_stc_subscriber_search_areas":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>L&#039;essai TUDCA n&#039;a pas r\u00e9pondu \u00e0 ses crit\u00e8res d&#039;\u00e9valuation &#8211; ALS Society of Canada<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L&#039;essai TUDCA n&#039;a pas r\u00e9pondu \u00e0 ses crit\u00e8res d&#039;\u00e9valuation &#8211; ALS Society of Canada\" \/>\n<meta property=\"og:description\" content=\"Le 4 avril 2024 \u2013 L&#8217;annonce des r\u00e9sultats globaux de l&#8217;essai clinique de phase 3 sur TUDCA en Europe a r\u00e9v\u00e9l\u00e9 que l&#8217;essai n&#8217;a pas r\u00e9pondu aux crit\u00e8res d&#8217;\u00e9valuation, \u00e9tant donn\u00e9 que TUDCA n&#8217;a pas d\u00e9montr\u00e9 sa capacit\u00e9 \u00e0 alt\u00e9rer de mani\u00e8re significative la progression de la SLA, selon les mesures de l&#8217;ALS Functional Rating [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/\" \/>\n<meta property=\"og:site_name\" content=\"ALS Society of Canada\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/\",\"url\":\"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/\",\"name\":\"L'essai TUDCA n'a pas r\u00e9pondu \u00e0 ses crit\u00e8res d'\u00e9valuation &#8211; ALS Society of Canada\",\"isPartOf\":{\"@id\":\"https:\/\/oldals.thedev.ca\/fr\/#website\"},\"datePublished\":\"2024-04-19T15:51:09+00:00\",\"dateModified\":\"2024-04-19T15:51:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/oldals.thedev.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nouvelles pour la communaut\u00e9 et m\u00e9dias\",\"item\":\"https:\/\/oldals.thedev.ca\/fr\/media-room\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"L&#8217;essai TUDCA n&#8217;a pas r\u00e9pondu \u00e0 ses crit\u00e8res d&#8217;\u00e9valuation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/oldals.thedev.ca\/fr\/#website\",\"url\":\"https:\/\/oldals.thedev.ca\/fr\/\",\"name\":\"ALS Society of Canada\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/oldals.thedev.ca\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'essai TUDCA n'a pas r\u00e9pondu \u00e0 ses crit\u00e8res d'\u00e9valuation &#8211; ALS Society of Canada","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"L'essai TUDCA n'a pas r\u00e9pondu \u00e0 ses crit\u00e8res d'\u00e9valuation &#8211; ALS Society of Canada","og_description":"Le 4 avril 2024 \u2013 L&#8217;annonce des r\u00e9sultats globaux de l&#8217;essai clinique de phase 3 sur TUDCA en Europe a r\u00e9v\u00e9l\u00e9 que l&#8217;essai n&#8217;a pas r\u00e9pondu aux crit\u00e8res d&#8217;\u00e9valuation, \u00e9tant donn\u00e9 que TUDCA n&#8217;a pas d\u00e9montr\u00e9 sa capacit\u00e9 \u00e0 alt\u00e9rer de mani\u00e8re significative la progression de la SLA, selon les mesures de l&#8217;ALS Functional Rating [&hellip;]","og_url":"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/","og_site_name":"ALS Society of Canada","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/","url":"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/","name":"L'essai TUDCA n'a pas r\u00e9pondu \u00e0 ses crit\u00e8res d'\u00e9valuation &#8211; ALS Society of Canada","isPartOf":{"@id":"https:\/\/oldals.thedev.ca\/fr\/#website"},"datePublished":"2024-04-19T15:51:09+00:00","dateModified":"2024-04-19T15:51:09+00:00","breadcrumb":{"@id":"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/oldals.thedev.ca\/fr\/salle-de-presse\/lessai-tudca-na-pas-repondu-a-ses-criteres-devaluation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/oldals.thedev.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Nouvelles pour la communaut\u00e9 et m\u00e9dias","item":"https:\/\/oldals.thedev.ca\/fr\/media-room\/"},{"@type":"ListItem","position":3,"name":"L&#8217;essai TUDCA n&#8217;a pas r\u00e9pondu \u00e0 ses crit\u00e8res d&#8217;\u00e9valuation"}]},{"@type":"WebSite","@id":"https:\/\/oldals.thedev.ca\/fr\/#website","url":"https:\/\/oldals.thedev.ca\/fr\/","name":"ALS Society of Canada","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oldals.thedev.ca\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"}]}},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/pages\/21382"}],"collection":[{"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/comments?post=21382"}],"version-history":[{"count":1,"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/pages\/21382\/revisions"}],"predecessor-version":[{"id":21383,"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/pages\/21382\/revisions\/21383"}],"up":[{"embeddable":true,"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/pages\/1569"}],"wp:attachment":[{"href":"https:\/\/oldals.thedev.ca\/fr\/wp-json\/wp\/v2\/media?parent=21382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}